⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Carbamic Acid SCHEMBL4444664 | 1.00 | ACHE (0.47) | — | |
| Bicarbonate SCHEMBL5083789 | 0.86 | — | — | |
| Acetic Acid SCHEMBL10353591 | 0.83 | FFAR3 (0.50) | — | |
| Oxalic Acid SCHEMBL29895907 | 0.83 | FFAR3 (0.41) | — | |
| Oxalic Acid SCHEMBL8730478 | 0.83 | FFAR3 (0.41) | — | |
| Acetic Acid SCHEMBL1362080 | 0.83 | — | — | |
| Propionic Acid SCHEMBL1362098 | 0.80 | FFAR3 (0.67) | — | |
| Carbamic Acid SCHEMBL9280663 | 0.80 | — | — | |
| Propionic Acid SCHEMBL1362611 | 0.80 | FFAR3 (0.67) | — | |
| SCHEMBL4958367 | 0.80 | TSHR (0.39) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 742 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0820440-A1 | NOVEL CARBAMATE COMPOUNDS HAVING N-SUBSTITUTED THIOCARBAMOYL GROUP AND PROCESS FOR PREPARING THE SAME | YUKONG LIMITED (KR) | 1998-01-28 | — | — | EP | claimed |
| WO-1996032378-A1 | NOVEL CARBAMATE COMPOUNDS HAVING N-SUBSTITUTED THIOCARBAMOYL GROUP AND PROCESS FOR PREPARING THE SAME | YUKONG LIMITED (KR) | 1996-10-17 | — | — | WO | claimed |
| US-11964943-B2 | 3,5-diarylidenyl-n-substituted-piperid-4-one-derived inhibitors of Stat3 pathway activity and uses thereof | KIAKOS KONSTANTINOS (AT) | 2024-04-23 | — | — | US | disclosed |
| US-20240108869-A1 | Active Agent Delivery Devices and Methods of Using the same | GLAS USA LLC | 2024-04-04 | — | — | US | disclosed |
| US-20240082147-A1 | Active Agent Loaded Uniform, Rigid, Spherical, Nanoporous Calcium Phosphate Particles and Methods of Making and Using the Same | LABORATORY SKIN CARE, INC. | 2024-03-14 | — | — | US | disclosed |
| US-20240058333-A1 | TREATMENT AND PREVENTION OF SLEEP DISORDERS | PURDUE PHARMA L.P. (US) | 2024-02-22 | — | — | US | disclosed |
| US-11865286-B2 | Active agent delivery devices and methods of using the same | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-01-09 | — | — | US | disclosed |
| US-20230414512-A1 | Dermal Delivery Compositions Comprising Active Agent-Calcium Phosphate Particle Complexes and Methods of Using the Same | LABORATORY SKIN CARE, INC. | 2023-12-28 | — | — | US | disclosed |
| US-20230293516-A1 | SLEEP DISORDER TREATMENT AND PREVENTION | PURDUE PHARMA L.P. (US) | 2023-09-21 | — | — | US | disclosed |
| US-11738023-B2 | Treatment and prevention of sleep disorders | PURDUE PHARMA L.P. (US) | 2023-08-29 | — | — | US | disclosed |
| EP-4218718-A2 | DERMAL DELIVERY COMPOSITIONS COMPRISING ACTIVE AGENT-CALCIUM PHOSPHATE PARTICLE COMPLEXES AND METHODS OF USING THE SAME | Laboratory Skin Care, Inc. (US) | 2023-08-02 | — | — | EP | disclosed |
| US-5308869-A | TREATMENT OR PROPHYLAXIS OF ANXIETY IN AN ANIMAL | STATE OF OREGON, ACTING BY AND THROUGH THE OREGON STATE BOARD OF HIGHER EDUCATION (US) | 1994-05-03 | — | — | US | disclosed |
| EP-0532642-A4 | — | — | 1994-04-27 | — | — | EP | disclosed |
| EP-0551330-A1 | SUBSTITUTED AMIDINES HAVING HIGH BINDING TO THE SIGMA RECEPTOR AND THE USE THEREOF | The STATE OF OREGON acting by and through the STATE BOARD OF HIGHER EDUCATION on behalf of the UNIV. OF OREGON (US) | 1993-07-21 | — | — | EP | disclosed |
| EP-0532642-A1 | SUBSTITUTED GUANIDINES HAVING HIGH BINDING TO THE SIGMA RECEPTOR AND THE USE THEREOF | STATE OF OREGON, acting through OREGON STATE BOARD OF HIGHER EDUCATION, acting for OREGON HEALTH SC. UNIV. AND UNIV. OF OREGON (US) | 1993-03-24 | — | — | EP | disclosed |
| EP-0473671-A4 | METHODS FOR TREATING ANXIETY WITH SIGMA RECEPTOR LIGANDS | — | 1992-04-01 | — | — | EP | disclosed |
| WO-1992004054-A1 | SUBSTITUTED AMIDINES HAVING HIGH BINDING TO THE SIGMA RECEPTOR AND THE USE THEREOF | STATE OF OREGON, acting by and through THE OREGON STATE BOARD OF HIGHER EDUCATION, acting for and on behalf of THE OREGON HEALTH SCIENCES UNIVERSITY, PORTLAND, OREGON, and THE UNIVERSITY OF OREGON, EUGENE, OREGON, Johnson Hall, University of Oregon (US) | 1992-03-19 | — | — | WO | disclosed |
| EP-0473671-A1 | USE OF SIGMA-RECEPTORS LIGANDS FOR THE MANUFACTURE OF AN ANXIOLYTIC AGENT. | OREGON STATE (US) | 1992-03-11 | — | — | EP | disclosed |
| WO-1991018868-A1 | SUBSTITUTED GUANIDINES HAVING HIGH BINDING TO THE SIGMA RECEPTOR AND THE USE THEREOF | STATE OF OREGON, acting by and through the OREGON STATE BOARD OF HIGHER EDUCATION, acting for and onbehalf of the OREGON HEALTH SCIENCES UNIVERSITY (US) | 1991-12-12 | — | — | WO | disclosed |
| WO-1990014067-A2 | METHODS FOR TREATING ANXIETY WITH SIGMA RECEPTOR LIGANDS | STATE OF OREGON, ACTING BY AND THROUGH THE OREGON STATE BOARD OF HIGHER EDUCATION, ACTING FOR AND ON BEHALF OF THE OREGON HEALTH SCIENCES UNIVERSITY AND THE UNIVERSITY OF OREGON (US) | 1990-11-29 | — | — | WO | disclosed |